8-6-4　ⓔ文献

  1. Myerburg RJ, Spooner PM: Opportunities for sudden death prevention: directions for new clinical and basic research. Cardiovasc Res, 2001; 50: 177–185.

  2. 河合忠一：突然死の調査研究. 昭和62年度厚生省循環器病研究委託費による研究報告集, 1987; 189.

  3. Myerburg RJ, Castellanos A: Cardiac arrest and sudden cardia death. Heart Disease. A textbook of cardiovascular medicine, 5th ed (Braunwald E ed), vol 2. WB Saunders, 1997; 742–779.

  4. 日本循環器学会：心臓突然死の予知と予防法のガイドライン (2010年改訂版)．2010.

  5. 総務省消防庁：令和元年版　救急救助の現況．2019.

  6. Bayes de Luna A, Coumel P: Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J, 1989; 117: 151–159.

  7. Wellens HJ, Schwartz PJ, et al: Risk stratification for sudden cardiac death: current status and challenges for the future. Eur Heart J, 2014; 35: 1642–1651.

  8. Kobayashi N, Hata N, et al: Characteristics of patients with cardiac arrest caused by coronary vasospasm. Circ J, 2013; 77: 673–678.

  9. Jayaraman R, Reinier K, et al: Risk Factors of Sudden Cardiac Death in the Young: Multiple-Year Community–Wide Assessment. Circulation, 2018; 137: 1561–1570.

  10. 日本循環器学会/日本不整脈心電学会合同ガイドライン：不整脈非薬物治療ガイドライン (2018 年改訂版)．2019.

  11. Shimizu A, Nitta T, et al: Actual conditions of implantable defibrillation therapy over 5 years in Japan. J Arrhythm, 2012; 28: 263–272.

  12. Ikeda T, Sakata T, et al: Combined assessment of T–wave alternans and late potentials used to predict arrhythmic events after myocardial infarction. A prospective study. J Am Coll Cardiol, 2000; 35: 722–730.

  13. Shimizu W, Makimoto H, et al: Association of Genetic and Clinical Aspects of Congenital Long QT Syndrome With Life–Threatening Arrhythmias in Japanese Patients. JAMA Cardiol, 2019; 4: 246–254.

  14. Boutitie F, Boissel JP, et al: Amiodarone interaction with beta–blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. Circulation, 1999; 99: 2268–2275.

  15. Watanabe H, Chopra N, et al: Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med, 2009; 15: 380–383.